In the ever-evolving landscape of beauty and wellness, the need for scientifically backed solutions that meet growing consumer demand for inner beauty products is stronger than ever. In a recent webinar, experts from Morinaga Milk Industry’s Food Functional Research Group, shine a light on the promising role of Bifidobacterium breve M-16V, a Human-Residential Bifidobacteria (HRB) strain, in enhancing skin health.
Host of the webinar, Dr. Ahmed Khan, senior analyst in GlobalData’s Consumer Division, tells us the concept of the gut-skin axis has gained significant traction in recent years, with research indicating that gut health plays a crucial role in skin health. As we age, the decline in bifidobacteria is linked to immune imbalance, increased inflammation, and accelerated skin aging. This decline presents a challenge for the beauty and wellness industry, as consumers increasingly seek products that offer both genuine efficacy and are rooted in scientific evidence.
According to Khan, GlobalData’s latest data shows that 38% of consumers globally say anti-ageing claims influence their cosmetics choices, rising to 44% among millennials, with nearly 30% buying personalised age-tailored solutions, aligned with their lifestyle. Meanwhile, around 40% of consumers are actively trying to improve their gut health. These figures highlight a powerful convergence of science, consumer demand and commercial opportunity in microbiome-based inner beauty.
The unique advantage of HRB strains
Morinaga Milk Industry, founded in Japan over 100 years ago, has built its probiotic research on decades of work in infant nutrition and human health. In 1969 it discovered its flagship strain BB536, and today its probiotics are used in more than 30 countries. Morinaga focuses on Human-Residential Bifidobacteria (HRB) strains that have co-evolved with humans and are highly compatible with the gut. Bifidobacteria dominate the infant gut but decline with age, a decline linked to disease risk across the lifespan. HRB strains, producing specific metabolites such as ILA, are therefore positioned as biologically relevant, scientifically grounded probiotic solutions. HRB strains, such as B. breve M-16V, differ fundamentally from conventional probiotics.
“Human-Residential Bifidobacteria have co-evolved with humans and are naturally adapted to the human intestine environment,” explains Kumiko Kato PhD, Manager, Clinical Trial Research Team at Morinaga Milk. This adaptation allows them to produce beneficial metabolites, such as acetic acid and ILA, which support gut barrier function and immune regulation. The compatibility of HRB strains with the human gut makes them particularly effective in delivering consistent gut-based benefits, which can translate into improved skin health.
What is the clinical evidence supporting M-16V?
The webinar highlights several clinical studies that underscore the potential of M-16V in supporting skin health. One notable study involves a double-blind, randomised controlled trial in adults with atopic dermatitis. “Intake of M-16V was associated with an increased proportion of intestinal bifidobacteria, and improvements were observed in symptom score and quality of life scores,” notes Hana Hasegawa, Researcher, Clinical Trial Research Team. “These results suggest a potential link between M-16V intake and skin-related outcomes in this population.”
Another study focused on healthy adult women, where M-16V intake resulted in significant improvements in skin parameters such as brown spots and pore appearance.
For brands in the beauty and wellness industry, the integration of clinically proven HRB solutions like M-16V offers a pathway to meet the rising consumer demand for safe, effective, and differentiating microbiome-based products. By leveraging the unique benefits of M-16V, brands can differentiate themselves in a crowded market and offer products that resonate with consumers seeking holistic health solutions.
Navigating regulatory landscapes
As the demand for microbiome-based products increases, so does the scrutiny around claims. Brands are encouraged to highlight the support of natural bodily functions, such as maintaining gut balance and supporting the immune system, rather than making therapeutic claims. Additionally, regional regulatory alignment is crucial, as claims and strategies must be adapted to meet the specific requirements of different markets.
From a manufacturing and compliance perspective, Kato highlights that “key consideration are strain status and the quality system on market-by-market basis,” pointing to US FDA GRAS status, EU QPS listing, internationally recognised quality systems such as FSSC 22000 with Halal and Kosher certifications, and registration of M-16V in China as a China New Food Raw Material for use in infant and toddler foods.
As consumers continue to seek products that support their overall health and well-being, the integration of HRB strains like M-16V into product portfolios can provide real, evidence-based value. By staying ahead of the curve with scientifically credible solutions, brands can not only meet consumer expectations but also thrive in the rapidly evolving market for inner beauty products.
Navigating the gut–skin space
This webinar brings together cutting-edge science on Human-Residential Bifidobacteria, real-world market insights, and practical guidance on claims and regulation. As Khan emphasises, “Education is key. We must educate our consumers on what the gut–skin axis is. It’s webinars like this that push that forward.”
Watch the session here to see how leading experts translate robust clinical evidence into credible, market-ready innovation.
